Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CalciMedicaCALC -24.73%29 3-Year EBITDA Growth Rate is 72.80% as of Mar. 2026, which is 50% above its 10-year median of 48.60. GuruFocus rates CALC with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,136 Biotechnology companies, CalciMedica ranks better than 94.19% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 72.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 55.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of CalciMedica was 72.80% per year. The lowest was -37.30% per year. And the median was 48.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CalciMedica 3-Year EBITDA Growth Rate Related Terms
CALC vs INTS, PHIO, INAB: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, CalciMedica's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CalciMedica 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CalciMedica's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CalciMedica's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 72.80% mean?
CalciMedica (CALC) has a 3-Year EBITDA Growth Rate of 72.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CalciMedica and its competitors. This is 50% above median its historical median of 48.60. According to the industry distribution chart, CalciMedica ranks #66 out of 1136 companies in the Biotechnology industry, placing it in the top 5.8%.
Is CalciMedica's 3-Year EBITDA Growth Rate too high?
CalciMedica's current 3-Year EBITDA Growth Rate of 72.80% is 50% above median its 10-year median of 48.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. CalciMedica's value of 72.80% is 390.2% above this industry median. Based on the distribution chart, CalciMedica ranks #66 out of 1136 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CalciMedica has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CalciMedica's 3-Year EBITDA Growth Rate compare to INTS and PHIO?
According to the Biotechnology industry distribution chart, CalciMedica ranks #66 out of 1136 companies for 3-Year EBITDA Growth Rate. This places CalciMedica in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. CalciMedica's value of 72.80% is 390.2% above this benchmark. While the company's 10-year median is 48.60 vs. the industry median of 14.85, CalciMedica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CalciMedica's current 3-Year EBITDA Growth Rate of 72.80% is 390.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CalciMedica and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CalciMedica's current 3-Year EBITDA Growth Rate is 72.80%, which is 50% above median its own 10-year median of 48.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CalciMedica stock overvalued right now?
CalciMedica (CALC) has a current 3-Year EBITDA Growth Rate of 72.80%. The current 3-Year EBITDA Growth Rate is 72.80%, which is 50% above median its 10-year median of 48.60 and 390.2% above the Biotechnology industry median of 14.85. CalciMedica's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CalciMedica (CALC), the current 3-Year EBITDA Growth Rate is 72.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
29GF Score
Get the complete analysis for CALC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALC has been successfully added to your 
